Update on the immunology, diagnosis and management of systemic lupus erythematosus

Internal Medicine Journal

Volumn 34, Issue 6, 2004, Pages 338-347

  Reeves, G E M ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Antinuclear antibodies; Autoimmune; Autoimmunity; Fibromyalgia; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CELECOXIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PREDNISONE; RITUXIMAB; ROFECOXIB;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CLINICAL FEATURE; COMMUNITY; DISEASE ACTIVITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; FIBROMYALGIA; GENETIC ANALYSIS; GENOME; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; LABORATORY; MAJOR HISTOCOMPATIBILITY COMPLEX; METHODOLOGY; MOLECULAR RECOGNITION; PATHOGENESIS; PHOTOSENSITIVITY; POLYMYOSITIS; POPULATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCLERODERMA; SCREENING; SERODIAGNOSIS; SJOEGREN SYNDROME; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEROLOGIC TESTS;

EID: 3242772892     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2004.00578.x     Document Type: Review

References (49)

1. Segasothy M, Phillips PA. Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: a comparative study. Lupus 2001; 10: 439-44.
2. Bossingham D. Systemic lupus erythematosus in the far north of Queensland. Lupus 2003; 12: 327-31.
3. Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian Aborigines: high prevalence, morbidity and mortality. Aust NZ J Med 1993; 23: 646-51.
4. Edworthy SM, Zatarain E, McShane DJ. Analysis of the 1982 ARA lupus criteria data set by recursive partitioning methodology. J Rheumatol 1988; 15: 1493-8.
5. Medzhitov R, Janeway C. Innate Immunity. N Engl J Med 2000; 343: 338-44.
6. Risch N. Searching for genes in complex diseases: lessons from systemic lupus erythematosus. J Clin Invest 2000; 105: 1503-6.
7. Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994; 152: 1453-61.
8. McIntosh R, Tighe P, Huggins M. Detection of retroviruses in systemic lupus erythematosus (SLE) and Behcet's disease (BD). Immunology 1999; 1 Suppl: 133.
9. Ventura A, Magazzu G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999; 117: 297-303.
10. Michael SD, Chapman JC. The influence of the endocrine system on the immune system. Immunol Allergy Clin North Am 1990; 10: 215-33.
11. Tan EM. Antinuclear antibodies; diagnostic markers for autoimmune diseases and probe for cell biology. Adv Immunol 1989; 44: 93-151.
12. Hochberg MC. Update of 1982 revised criteria for the classification of SLE. Arthritis Rheum 1997; 40: 1725.
13. Aronowitz RA. When do symptoms become a disease? Ann Intern Med 2001; 134: 803-8.
14. Uramoto KM, Michet CJ Jr, Thumboo J. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50.
15. Levin DL, Roenigk HH, Caro WA. Histologic, immunofluorescent, and antinuclear antibody findings in PUVA-treated patients. J Am Acad Dermatol 1982; 6: 328-33.
16. Nitta Y, Muramatsu M. A juvenile case of overlap syndrome of systemic lupus erythematosus and polymyositis, later accompanied by systemic sclerosis with the development of anti-Scl 70 and anti-Ku antibodies. Pediatric Dermatol 2000; 17: 381-3.
17. Deane PMG, Liard G, Siegel DM. The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease. Pediatrics 1995; 95: 892-5.
18. Grabar P. Autoantibodies and the physiological roles of immunoglobulins. Immunol Today 1983; 4: 387-42.
19. Sackett DL. Evaluation of clinical method. In: Weatherall DJ, Ledingham JG, Warrell DA, eds. Oxford Textbook of Medicine. Oxford: Oxford University Press; 1996; 19-20.
20. Friedman AW, Graciela S, Alarcón GM Jr. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. Arthritis Care Res 1999; 12: 256-66.
21. Bonfa E, Elkon KB. Clinical and serological associations of the antiribosomal P protein antibody. Arthritis Rheum 1986; 29: 981-5.
22. Notman DD, Kurata N, Tan EM. Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med 1975; 83: 464-9.
23. Favoloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118: 548-57.
24. Lock RJ, Unsworth DJ. Antibodies to extractable nuclear antigens. Has technological drift affected clinical interpretation? J Clin Pathol 2001; 54: 187-90.
25. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1995; 38: 826-34.
26. Tench CM, McCurdie I, White PD. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology 2000; 39: 1249-54.
27. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology 2000; 39: 238-44.
28. Cervera R, Khamashta MA, Font J. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine 1993; 72: 113-24.
29. Shapiro S. Psychopathology in the patient with lupus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus. Baltimore: Williams & Wilkins; 1997; 7755-82.
30. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001; 134: 868-81.
31. Branch VK, Lipsky K, Nieman T. Positive impact of an intervention by arthritis patient educators on knowledge and satisfaction of patients in a rheumatology practice. Arthritis Care Res 1999; 12: 370-75.
32. Creamer P, Singh BB, Hochberg MC. Sustained improvement produced by non-pharmacological intervention in fibromyalgia: Results of a pilot study. Arthritis Care Res 2000; 13: 198-204.
33. Barlow JH, Turner AP, Wright CC. A randomized controlled study of the Arthritis Self-Management Programme in the UK. Health Educ Res 2000; 15: 665-80.
34. Lorig KL, Holman H, Sobel D. Living a Healthy Life with Chronic Conditions. California: Bull Publishing; 1994; 27-32.
35. Tsakonas E, Joseph L, Esdaile JM. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998; 7: 80-85.
36. Michet CJ, McKenna CH, Elveback LR. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985; 60: 105-13.
37. Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population-based study. J Rheumatol 2000; 27: 1884-91.
38. Wallace DJ. Management of lupus erythematosus: recent insights. Curr Opin Rheumatol 2002; 14: 212-19.
39. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 238-44.
40. Cameiro JR, Sato EI. Double-blind randomised, placebo-controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26: 1275-9.
41. Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969-74.
42. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001; 10: 480-83.
43. Chan TM, Li FK, Tang CSO. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62.
44. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 2002; 14: 220-24.
45. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002; 206: 519-27.
46. Logan RA, Nuttall RJ, Hazelwood SE. Audience motivations to use an arthritis website. Arthritis Care Res 2000; 13: 320-29.
47. Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient non-adherence. Arthritis Care Res 2000; 13: 406-8.
48. Brenner R, Azbel V, Madhusoodanan S. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomised pilot study. Clin Ther 2000; 22: 411-19.
49. Montanaro A, Bardana EJ Jr. Dietary amino acid induced systemic lupus erythematosus. Rheum Dis North Am 1991; 17: 323-32.